Skip to main content

Table 1 Baseline Characteristics

From: Outcomes of Cardiac Resynchronization Therapy in Patients with Hypothyroidism and Heart Failure

Variable

All (n = 1316)

Euthyroidism (n = 966)

Hypothyroidism (n = 350)

P Value

Age, y

69.8 ± 12.2

69.3 ± 12.4

71.2 ± 11.2

0.01

Female

289 (22.0)

184 (19.0)

105 (30.0)

< 0.001

CRT-D

1181 (89.7)

867 (89.7)

314 (90.0)

0.87

Primary prevention

979 (82.9)

749 (86.5)

230 (73.0)

< 0.001

Hypertension

539 (41.0)

398 (41.2)

141 (40.4)

0.81

Diabetes mellitus

398 (30.2)

297 (30.7)

101 (28.9)

0.54

Chronic kidney disease

357 (27.1)

248 (25.7)

109 (31.2)

0.04

Hyperlipidemia

600 (45.7)

442 (45.7)

158 (45.4)

0.92

Atrial fibrillation history

599 (44.5)

430 (44.5)

169 (48.4)

0.20

ICM

632 (48.0)

462 (47.8)

170 (48.7)

0.77

LBBB

644 (40.1)

491 (52.2)

153 (44.5)

0.02

QRS duration, ms

170.2 ± 28.5

169.5 ± 28.2

172.1 ± 29.4

0.16

NYHA functional class, 1–4

2.8 ± 0.6

2.8 ± 0.6

2.9 ± 0.5

0.64

 3–4

892

644 (69.7)

248 (73.6)

 

 2

349

264 (28.6)

85 (25.2)

 

 1

20

16 (1.7)

4 (1.2)

 

LVEF, %

24.3 ± 6.5

24.2 ± 6.6

24.4 ± 6.6

0.62

TRT

254 (19.3)

0 (0)

254 (72.9)

< 0.001

Amiodarone

232 (17.6)

135 (14.0)

97 (27.9)

< 0.001

Statin

705 (53.6)

529 (54.7)

176 (50.4)

0.17

Digoxin

539 (41.0)

391 (40.4)

148 (42.4)

0.52

β-blocker

1156 (87.8)

853 (88.2)

303 (86.8)

0.50

ACEI/ARB

1054 (80.1)

781 (80.8)

273 (78.2)

0.31

Aldactone

391 (29.7)

288 (29.8)

103 (29.5)

0.93

Furosemide

886 (67.3)

640 (66.2)

246 (70.5)

0.14

  1. Values are count (%) or mean ± SD
  2. Abbreviations: ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CRT-D cardiac resynchronization therapy-defibrillator, ICM ischemic cardiomyopathy, LBBB left bundle branch block, LVEF left ventricular ejection fraction, NYHA New York Heart Association, TRT thyroid replacement therapy